

# CCT 137690

Catalog No: tcsc0706



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1095382-05-0

**Formula:**

$C_{26}H_{31}BrN_8O$

**Pathway:**

Cell Cycle/DNA Damage;Epigenetics

**Target:**

Aurora Kinase;Aurora Kinase

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

551.48

## Product Description


CCT 137690 is a potent and orally available **aurora** kinase inhibitor with **IC<sub>50</sub>**s of 15, 25, and 19 nM for aurora A, B and C,

respectively.

IC50 & Target: IC50: 15 nM (Aurora A), 25 nM (Aurora B), 19 nM (Aurora C)<sup>[1]</sup>

**In Vitro:** CCT 137690 displays antiproliferative activity in a range of human tumor cell lines, including SW620 colon carcinoma ( $GI_{50}$  = 0.30  $\mu$ M) and A2780 ovarian cancer cell line ( $GI_{50}$  = 0.14  $\mu$ M). CCT 137690 inhibits *in vitro* phosphorylation of histone H3. CCT 137690 is a moderate inhibitor of the hERG ion-channel ( $IC_{50}$  = 3.0  $\mu$ M)<sup>[1]</sup>. CCT137690 efficiently inhibits histone H3 and TACC3 phosphorylation (Aurora B and Aurora A substrates, respectively) in HCT116 and HeLa cells. Continuous exposure of tumour cells to the inhibitor causes multipolar spindle formation, chromosome misalignment, polyploidy and apoptosis<sup>[2]</sup>.

**In Vivo:** CCT 137690 slows the growth of the SW620 xenografts with no observed toxicity<sup>[1]</sup>. CCT 137690 significantly inhibits tumour growth in a transgenic mouse model of neuroblastoma (TH-MYCN) that overexpresses MYCN protein and is predisposed to spontaneous neuroblastoma formation<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!